In March 2024, the FDA further approved Wegovy to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight
Dermatology (Basel) 189, 225233
Proteomic analysis of the Arabidopsis thaliana - Botrytis cinerea interaction using two-dimensional liquid chromatography
Their edible nature and cultural acceptance also reduce downstream purification requirements, making direct oral administration of bioencapsulated recombinant products feasible
This option is also used for migraine headaches, stress management and to promote overall wellness
Hims said in a separate press release that as part of the deal, it "will no longer advertise compounded GLP-1 offerings on its platform or in its marketing, and existing patients will have the opportunity to transition to FDA-approved medicines when determined clinically appropriate by their providers." The deal ends an ongoing conflict between the two companies over allegations from Novo Nordisk that Hims was distributing copycat versions of its Wegovy weight-loss pill and violating patent protections
